13. CC, CC @ CHLNV, and blank CC @ CHLNV arrests Lewis
lung cancer cell cycle in S phase. The proportions of cells in S
phase after treatment with CC, CC @ CHLNV, and blank CC
@ CHLNV groups should be (81.57 Æ 9.15)%,
(92.20 Æ 7.65)%, and (64.43 Æ 10.12)%, respectively.
14. There are quenching problems in fluorescent dyes. Keep in the
dark during storage and use to slow down fluorescence
quenching.
15. In the early stage of apoptosis, different types of cells will turn
phosphatidylserine out to the cell surface. Annexin V selectively binds phosphatidylserine. Annexin V labeled with FITC
(Annexin V-FITC), a green fluorescent probe, can be used to
detect the eversion of phosphatidylserine, an important feature
of apoptosis, directly and simply by flow cytometry. Propidium
iodide can stain the cells that lose the integrity of cell membrane in the late stage of apoptosis, showing red fluorescence.
16. In the CC group and CC@CHLNV group, the intracellular
reactive oxygen species fluorescence intensity of Lewis lung
cancer cells should be (2088.01 Æ 238.19) and
(2568.67 Æ 361.85), respectively.
17. In the CC group and CC@CHLNV group, the intracellular
calcium ion fluorescence intensities of Lewis lung cancer cells
are expected to be (52.11 Æ 11.28) and (97.85 Æ 15.68),
respectively.
18. In the CC group and CC@CHLNV group, the expected mitochondrial membrane potential fluorescence intensities of Lewis
lung cancer cells are (128.97 Æ 18.56) and (94.00 Æ 12.11),
respectively.
19. Weigh and record the body weight of the mice every other day.
20. Expected results: The tumor volume of CC@CHLNV group
should decrease with prolonged administration time, and the
tumor mass of CC@CHLNV group should shrink compared to
other groups.
References
1. Yan S, Liu Y, Feng J, Zhao H, Yu Z, Zhao J,
Li Y, Zhang J (2018) Difference and alteration
in pharmacokinetic and metabolic characteristics of low-solubility natural medicines. Drug
Metab Rev 50:140–160
2. Wan K, Sun L, Hu X, Yan Z, Zhang Y,
Zhang X, Zhang J (2016) Novel nanoemulsion
based lipid nanosystems for favorable in vitro
and in vivo characteristics of curcumin. Int J
Pharm 504:80–88
3. Tan Q, Liu S, Chen X, Wu M, Wang H, Yin H,
He D, Xiong H, Zhang J (2012) Design and
evaluation of a novel evodiamine-phospholipid
complex for improved oral bioavailability.
AAPS PharmSciTech 13:534–547
4. Zhang JQ, Liu J, Li XL, Jasti BR (2007) Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv
14:381–387
Catanionic Hybrid Lipid Nanovesicles
67
lung cancer cell cycle in S phase. The proportions of cells in S
phase after treatment with CC, CC @ CHLNV, and blank CC
@ CHLNV groups should be (81.57 Æ 9.15)%,
(92.20 Æ 7.65)%, and (64.43 Æ 10.12)%, respectively.
14. There are quenching problems in fluorescent dyes. Keep in the
dark during storage and use to slow down fluorescence
quenching.
15. In the early stage of apoptosis, different types of cells will turn
phosphatidylserine out to the cell surface. Annexin V selectively binds phosphatidylserine. Annexin V labeled with FITC
(Annexin V-FITC), a green fluorescent probe, can be used to
detect the eversion of phosphatidylserine, an important feature
of apoptosis, directly and simply by flow cytometry. Propidium
iodide can stain the cells that lose the integrity of cell membrane in the late stage of apoptosis, showing red fluorescence.
16. In the CC group and CC@CHLNV group, the intracellular
reactive oxygen species fluorescence intensity of Lewis lung
cancer cells should be (2088.01 Æ 238.19) and
(2568.67 Æ 361.85), respectively.
17. In the CC group and CC@CHLNV group, the intracellular
calcium ion fluorescence intensities of Lewis lung cancer cells
are expected to be (52.11 Æ 11.28) and (97.85 Æ 15.68),
respectively.
18. In the CC group and CC@CHLNV group, the expected mitochondrial membrane potential fluorescence intensities of Lewis
lung cancer cells are (128.97 Æ 18.56) and (94.00 Æ 12.11),
respectively.
19. Weigh and record the body weight of the mice every other day.
20. Expected results: The tumor volume of CC@CHLNV group
should decrease with prolonged administration time, and the
tumor mass of CC@CHLNV group should shrink compared to
other groups.
References
1. Yan S, Liu Y, Feng J, Zhao H, Yu Z, Zhao J,
Li Y, Zhang J (2018) Difference and alteration
in pharmacokinetic and metabolic characteristics of low-solubility natural medicines. Drug
Metab Rev 50:140–160
2. Wan K, Sun L, Hu X, Yan Z, Zhang Y,
Zhang X, Zhang J (2016) Novel nanoemulsion
based lipid nanosystems for favorable in vitro
and in vivo characteristics of curcumin. Int J
Pharm 504:80–88
3. Tan Q, Liu S, Chen X, Wu M, Wang H, Yin H,
He D, Xiong H, Zhang J (2012) Design and
evaluation of a novel evodiamine-phospholipid
complex for improved oral bioavailability.
AAPS PharmSciTech 13:534–547
4. Zhang JQ, Liu J, Li XL, Jasti BR (2007) Preparation and characterization of solid lipid nanoparticles containing silibinin. Drug Deliv
14:381–387
Catanionic Hybrid Lipid Nanovesicles
67